OneMedNet Announces Strong 2025 Financials and Advances AI-Driven iRWD™ powered by Palantir Foundry enabling Conversational Search on Real-Time Medical Data
Rhea-AI Summary
OneMedNet (Nasdaq: ONMD) reported strong 2025 results driven by its AI‑driven iRWD™ platform powered by Palantir Foundry. Key 2025 metrics include RWD revenue up 329% YoY to $1.254M, Q4 revenue above $890,000, and total liabilities cut 74% to $5.1M.
The company reduced its shareholder deficit to $(3.0M), has 2 pilot customers in contracting, expects 4 additional seven‑figure subscription customers in H2 2026, and projects 4x platform growth by end of 2026.
Positive
- RWD revenue +329% YoY to $1.254M
- Q4 revenue climbed to over $890,000
- Total liabilities reduced 74% to $5.1M
- Shareholder deficit improved to $(3.0M)
- 2 pilots in contracting; 4 customers expected in Q2–Q3 2026
- Platform projected 4x growth by end of 2026
Negative
- Company still reports a shareholder deficit of $(3.0M)
- 2025 RWD revenue of $1.254M is modest in absolute scale
- Balance sheet improvement partly via settlements and debt-to-equity conversions
News Market Reaction – ONMD
In the Apr 6 session, ONMD gained 2.40%, reflecting a moderate positive market reaction. Argus tracked a peak move of +10.1% during that session. Argus tracked a trough of -11.3% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 3.1x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | AI RWD collaboration | Positive | -0.8% | Collaboration to use iRWD™ for oncology real-world data and model development. |
| Jan 22 | AI FDA support | Positive | +12.1% | ONMD data supported FDA 510(k) clearance of AI BrainCT-ICH software. |
| Nov 10 | AI platform launch | Positive | +4.7% | Launch of Palantir-powered iRWD™ subscription platform with AI search features. |
| Oct 06 | Palantir AI deal | Positive | +148.5% | Multi-year Palantir AI Platform agreement to power iRWD™ data analytics. |
| Jul 31 | AI oncology project | Positive | +3.8% | Inka Health selected for AI-driven oncology project using iRWD external control arms. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-tagged announcements for ONMD have mostly produced positive price reactions, with 4 of 5 prior events moving up within 24 hours and only one small negative divergence.
Over the past year, ONMD has repeatedly highlighted AI-driven, Palantir-powered real-world data initiatives. Prior AI-tagged releases covered platform launches, multi-year agreements with Palantir, and collaborations supporting FDA 510(k) clearance and oncology projects. These updates generally coincided with positive price moves, including a 148.54% jump on the Palantir agreement. Today’s 2025 financials and iRWD™ progress extend that narrative by pairing commercial traction and balance-sheet improvement with the same AI RWD strategy.
Key Terms
real-world data (rwd) medical
debt-to-equity conversions financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, April 06, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), highlights its 2025 results, with robust revenue growth from the prior year, a strengthened balance sheet, and continued commercial momentum driven by Palantir Foundry enabled conversational search on Real-Time medical data from OneMedNet’s rapidly growing network.
2025 Financial Highlights:
- RWD Revenue Growth:
- RWD revenue increased
329% year-over-year, rising from$292,000 in 2024 to$1,254,000 in 2025, reflecting strong market demand and increased commercial traction.
- RWD revenue increased
- Fourth Quarter Revenue Acceleration:
- Our work towards building and executing upon our strategy came together during the quarter ended December 31, 2025 with revenue surging to over
$890,000 .
- Our work towards building and executing upon our strategy came together during the quarter ended December 31, 2025 with revenue surging to over
- Bookings Momentum:
- Revenue growth is beginning to align with previously disclosed increases in bookings, reinforcing the Company’s transition toward a scalable, subscription-based model.
- Total Liabilities Reduced by
74% :- Total liabilities decreased from
$19.7 million at December 31, 2024 to$5.1 million at December 31, 2025. - Driven by a combination of negotiated settlements and debt-to-equity conversions.
- Total liabilities decreased from
- Equity Position Improved:
- Shareholder deficit substantially reduced from
$(16.0) million to$(3.0) million .
- Shareholder deficit substantially reduced from
Building upon next commercial phase momentum:
- Following its February 2026 announcement, OneMedNet entered a new phase of commercial execution centered on its AI-driven iRWD™ platform powered by Palantir Foundry, with the following commercial highlights:
- 2 Pilot Customers in contracting.
- 4 Additional customers expected in the second and third quarter of 2026, each representing a seven-figure subscription revenue potential over the term of the contract.
- Advanced stage pipeline of additional multi-year subscription opportunities.
- Early Verbal Customer Feedback of the OneMedNet Platform:
- Cohort discovery timelines reduced from weeks to minutes - Significant improvements in feasibility analysis and dataset precision.
- Ability to query over a billion data points with results returned in seconds.
- Platform Scale and Network Expansion Outlook:
- OneMedNet accelerates its provider network expansion and overall data scale, enabling the Company to fulfill additional orders and deliver greater value to subscription customers.
- Projected 4x growth in the platform by the end of 2026.
“Our 2025 performance marks a pivotal turning point for OneMedNet,” said Aaron Green, CEO & President. “We have successfully sunset our BEAM solution along with the expenses associated with it, allowing us to focus fully on our Real-World Data business achieving meaningful revenue acceleration, dramatically improving our balance sheet, and launching the next generation of our platform. We believe the early response from customers validates our strategy — delivering real-world data with the speed, scale, and intelligence required to power modern healthcare innovation. Looking ahead to 2026, we will continue to build and execute on this strategy and expect revenues to grow substantially.”
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information.
Learn more at www.onemednet.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our products, plans and strategies, our expected growth in the business, and our ability to achieve our operational strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION
